Search research articles
Contact Us
Filters
Showing results (91-100 of 1,559) with videos related to
Page
of 156
Sort By:
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|
June 17, 2009
[Preventive effect of integrative medical therapy on children Henoch-Schonleln purpura with renal impairment]
Hong Zhao, Zhi-Yan Dou, Yu-Qiu Li
Clinical and Experimental Medicine
|
April 24, 2023
Ubiquitin-specific peptidase 1: assessing its role in cancer therapy
Peng Huang, YuHan Wang, PengFei Zhang, et al.
Journal of Medical Economics
|
January 17, 2019
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Weiting Liao, Jiaxing Huang, David Hutton, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
January 4, 2013
Bis{2-[imino-(phen-yl)meth-yl]-5-meth-oxy-phenolato-κ(2)N,O(1)}nickel(II)
Yu Xiao, Zhong-Qiu Li, Xue Yan Peng
Frontiers in Public Health
|
May 27, 2022
Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
Mingyang Feng, Yue Chen, Yang Yang, et al.
Expert Opinion on Therapeutic Patents
|
December 31, 2016
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Hai-Tao Qin, Huan-Qiu Li, Feng Liu
Life Sciences
|
March 16, 2024
The tale of SOX2: Focusing on lncRNA regulation in cancer progression and therapy
Peng Huang, Feng Wen, YiShan Li, et al.
Biochemical Genetics
|
September 14, 2024
LncRNA HAND2-AS1 Inhibited Colon Cancer Progression By Regulating miR-3118/ZG16 Axis
Ling Hu, Linfeng Xie, Shan Huang, et al.
Frontiers in Pharmacology
|
June 2, 2023
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
Kexun Zhou, Pei Shu, Hanrui Zheng, et al.
Cost Effectiveness and Resource Allocation : C/E
|
September 13, 2023
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
Peng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Page
of 156
Search research articles
Search
Showing results (91-100 of 1,559) with videos related to
Sort By:
Page
of 156
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|
June 17, 2009
[Preventive effect of integrative medical therapy on children Henoch-Schonleln purpura with renal impairment]
Hong Zhao, Zhi-Yan Dou, Yu-Qiu Li
Clinical and Experimental Medicine
|
April 24, 2023
Ubiquitin-specific peptidase 1: assessing its role in cancer therapy
Peng Huang, YuHan Wang, PengFei Zhang, et al.
Journal of Medical Economics
|
January 17, 2019
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
Weiting Liao, Jiaxing Huang, David Hutton, et al.
Acta Crystallographica. Section E, Structure Reports Online
|
January 4, 2013
Bis{2-[imino-(phen-yl)meth-yl]-5-meth-oxy-phenolato-κ(2)N,O(1)}nickel(II)
Yu Xiao, Zhong-Qiu Li, Xue Yan Peng
Frontiers in Public Health
|
May 27, 2022
Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
Mingyang Feng, Yue Chen, Yang Yang, et al.
Expert Opinion on Therapeutic Patents
|
December 31, 2016
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Hai-Tao Qin, Huan-Qiu Li, Feng Liu
Life Sciences
|
March 16, 2024
The tale of SOX2: Focusing on lncRNA regulation in cancer progression and therapy
Peng Huang, Feng Wen, YiShan Li, et al.
Biochemical Genetics
|
September 14, 2024
LncRNA HAND2-AS1 Inhibited Colon Cancer Progression By Regulating miR-3118/ZG16 Axis
Ling Hu, Linfeng Xie, Shan Huang, et al.
Frontiers in Pharmacology
|
June 2, 2023
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
Kexun Zhou, Pei Shu, Hanrui Zheng, et al.
Cost Effectiveness and Resource Allocation : C/E
|
September 13, 2023
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
Peng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Page
of 156